FCE 22891, a synthetic &beta;-lactam antibiotic of the penem class, was administered by gavage to Sprague-Dawley rats and cynomolgus monkeys for 26 wk (with and without a 6-wk recovery). Rats received the test material at doses of 0, 200, 500, and 1,250 mg/kg/day, and monkeys were given doses of 0, 100, 200, 400, and 600 mg/kg/day. At the end of the 26-wk treatment period, approximately two-thirds of the animals (both species) were sacrificed, and the remaining animals were held without treatment for a further 6 wk. A treatment-related mortality occurred in female monkeys receiving 600 mg/kg. There was a reduction in body weight gain in the high-dose groups of both species. Male rats were more affected than the females and, conversely, female monkeys were affected more than the males. At higher dose levels, both species exhibited an early, but transient, azotemia and oliguria with an increase in specific gravity and reduced pH. In rats, microscopic examination revealed treatment-related renal cortical tubular degenerative and regenerative changes with associated interstitial inflammation and fibrosis and diffuse urothelial hyperplasia in the urinary bladder. In general, female rats were less severely affected, and in both sexes there was a trend to recovery of most of these effects. In monkeys given 600 mg/kg of the test material, renal cortical tubular degeneration was seen only in those females that died in the first 5 wk of dosing. In other animals at this dose level, the renal lesions were determined to be reversible.
INTRODUCTION
Penems are a new class of synthetic fl-lactam antibiotics that includes penicillins, cephalosporins, and several other structurally related compounds. Several penems have demonstrated nephrotoxicity in a few laboratory animal species and in humans (15, (20) (21) (22) . The potential of penems to elicit Type II hypersensitivity reactions manifested by anemia or neutropenia in monkeys and anemia, neutropenia, and thrombocytopenia in rats has been reported (16) , as has the risk for eliciting epileptogenic reactions when administered into the cerebral cisterns (18) . The effect on blood coagulation parameters has also been investigated (17) . It was found that some of these antibiotics inhibit liver microsomal vitamin K epoxide reductase in rats.
FCE 22891 is an orally administered synthetic (3- lactam antibiotic of the penem class. It is a prodrug, being rapidly hydrolyzed after intestinal absorption by tissue and serum esterases to the parent compound FCE 22101 ( Fig. 1 ). FCE 22101 is effective against gram-positive and gram-negative bacteria and is resistant to ~3-lactamases.
The studies described in this article were undertaken to elucidate the toxic potential of FCE 22891 1 when administered by daily gavage to Sprague-Dawley rats and cynomolgus monkeys for 26 wk and to determine whether or not any effects were reversible during a 6-wk recovery period.
MATERIALS AND METHODS
The 2 studies reported here were carried out in the laboratories of Pharmacia Farmitalia C.Erba (previously known as Farmitalia Carlo Erba), Milan, Italy. They were performed in accordance with the principles of good laboratory practice (OECD principles of Good Laboratory Practice), and all phases of the study were inspected by the Quality Assurance Unit. All animals were treated in a humane manner and received complete veterinary care according to EEC law 86/609. Test Material. FCE 22891, acetoxymethyl-(5R, 6S)-2-carbamoyloxyrnethyl~6-[( R)-hydroxyethyl]-2-penem-3-carboxylate ( Fig. 1 ), was synthesized by Farmitalia Carlo Erba of Milan, Italy. The test material (90-91% pure) was suspended in an aqueous solution of 0.5% methocel (methylcellulose 400) and was administered to rats and monkeys in accordance with the treatment and the experimental design shown in Table I . Individual dose volumes were adjusted to the last recorded body weight. The control groups received 0.5% methocel only. The stability of the suspensions and their concentrations were checked during the studies. Dose levels for these studies were based on the results of previous subchronic studies. and the route of administration was chosen as that intended for use in humans.
Animals. Two hundred forty ( 120 males and 120 Sixty cynomolgus monkeys (30 males and 30 females) weighing 2-3 kg were supplied by Charles River Primates Import Corporation (USA) and Shamrock Farms (UK). The monkeys were examined on arrival and were found to be tuberculinnegative. They were acclimatized for about 2 mo, identified by a number tattooed on the arm or breast, and kept I to each cage at a controlled temperature of 22.5 ± 1.5°C, with a humidity of 55 ± 12.5% and lighting with a 12-hr cycle of light and dark.
The animals were provided with tap water in bottles, and each received 150 g ofaltromin A pelleted feed (A. Rieper Vandoies-Bolzano, Italy) and fresh fruit or vegetables each day. Table I shows the group   distribution and treatments. Clinical Observations. The animals in both studies were under veterinary supervision at all times. In the rat study, mortality, behavior, and physical condition were observed daily, and body weights were recorded on day I and weekly for the first 3 mo and every 2 wk thereafter for the duration of the treatment and recovery periods. Food con-sumption was measured by cage at weekly intervals for the first 3 mo and monthly thereafter. Water consumption was measured over a 24-hr period for each cage on 2 consecutive days per month for the duration of the study. In the monkey study, mortality, behavior, physical condition, and food consumption were recorded daily, and body weights were recorded on days -14, -7, and 1 and weekly thereafter for the duration of the study.
For both species, ophthalmoscopy examinations using an indirect ophthalmoscope, and a slit lamp when necessary, were performed on day 0, at 26 wk, and at the end of the 6-wk recovery period. Mydriasis was achieved by application of 0.5% and 1.0% tropicamide in rats and monkeys, respectively. Clinical ChemistrylHematology. In the rat, blood was obtained under ether anesthesia from the sublingual veins from 10 rats of each sex per group at 4 and 13 wk and from all surviving rats at 26 and 32 wk. In the monkeys, blood was obtained from the femoral vein in the morning after overnight fasting. Samples were collected prior to the study, at the end of weeks 1 and 11, prior to the terminal sacrifice at 26 wk and at the end of the recovery period. Blood samples were collected in 8% EDTA for hematological examinations and in serum tubes for clinical chemistry determinations. For hematological examinations, the following parameters were determined for both species: red blood cell count, hemoglobin, hematocrit, mean corpuscular hemoglobin, mean corpuscular volume, white blood cell (WBC) count, neutrophil, eosinophil, basophil, lymphocyte, monocyte, and platelet counts. In addition, a WBC-differential count was performed on blood smear samples from rats taken at the following intervals : at 26 wk from all males and from female high-dose animals and controls; in weeks 5, 13, and 32 from high-dose and control males; and in weeks 13 and 32 from males only receiving 500 mg/kg.
In the monkey study, additional coagulation tests were carried out on samples of blood to which 3.8% sodium citrate was added at a volume of 1 to 10.
Fibrinogen, partial thromboplastin time, and prothrombin time were determined. Blood samples, which were collected in tubes for serum separation, were examined for the following parameters (in both species): glucose, total protein, albumin, urea, creatinine, total cholesterol, triglycerides, phospholipids, total bilirubin. aspartate aminotransferase, alkaline phosphatase, calcium, sodium, and potassium.
Crinalysis. In rats, urine was collected overnight after about 5 ml of tap water had been given by gavage. Food was witheld during this time. Ap-proximately 0.5 ml of 1 % thimerosal was added as an antifermentative to each sample. In monkeys, collection took place during a fast of 16 hr, and 2 ml of 1 % thimerosal was added to each sample. The following parameters were determined in both rats and monkeys: appearance, color, volume, specific gravity, pH, sodium, potassium, protein, nitrates, glucose, ketones, urobilinogen, bilirubin, hemoglobin, red and white cells, and microscopy of sediment.
Necropsy. All animals, including those that died or were sacrificed preterminally or scheduled at termination or after the recovery period were subjected to a complete gross examination. For scheduled sacrifices, rats were fasted overnight and sacrificed by exsanguination from the abdominal aorta under sodium thiopental anesthesia. The following organs were weighed: adrenals, brain, kidneys, heart, liver, ovaries, pituitary, prostate, spleen, thymus, testes, and uterus. The fasted final body weight was used for calculation of the relative weights. The monkeys were also fasted overnight, weighed, and sacrificed by exsanguination from the femoral vein under sodium thiopental anesthesia. The same organs were weighed as those in the rats, and relative weights were calculated against the fasted body weight.
Microscopic Examination. The following tissues were sampled and fixed in 10% neutral-buffered formalin : adrenals, aortic arch, bone marrow smear, brain, cecum, colon, duodenum, epididymides, esophagus, eyes with optic nerves, heart, ileum, jejunum, kidneys, lacrimal glands, liver, lungs, mesenteric lymph nodes, ovaries, pancreas, pituitary, prostate, rectum, sciatic nerve, seminal vesicles, skin with inguinal mammary glands, biceps femoris muscle, spleen, cervical and thoracic portions ofspinal cord, stemebrae, stomach, submaxillary salivary glands, tongue, testes, thymus, thyroids with parathyroids, trachea, urinary bladder, ureters, and uterus. For the rats, microscopic examination was limited to all these tissues from control and high-dose level animals only while the kidneys, urinary bladder, and all grossly abnormal organs were examined from all other animals. Histological examination was done on sections embedded in paraffin and stained with hematoxylin and eosin. Bone marrow smears were fixed in methanol ether and stained with May-Grfnwald-Giemsa.
The same tissues as for the rats were examined in the monkeys with the addition of the following: gallbladder, optic nerves and mammary glands processed separately, lumbar spinal cord, and parotid salivary glands.
Statistical Analysis. Values for body weights, organ weights, clinical chemistry, hematology, urinary volume, specific gravity, pH, sodium, and potassi-TABLE IL-Mean body weights in rats (g) and monkeys (kg) treated with FCE 2'89 for 26 wk followed by 6 wk
In the recovery group at 28 R and 32 R, the mean weight is from 2 animals. At all other intervals, the mean weight is from 6 animals, except for those noted with *, which denotes the mean weight of 3 animals. In the high-dose females,-indicates that there were no animals left alive at this dose after 4 wk.
um were expressed as means ± SEM, and their statistical significance at either p < 0.05 or p < 0.01 was calculated comparing means from controls and treated groups. Specifically, Dunn's test (3) was used for differential WBC counts and Dunnett's test (4) for organ weights either after adjustment using a 1 -way analysis of variance (11) after applying analysis of variance for body weights and after applying heterogeneous variances (23) for hematology, clinical chemistry, and urinary parameters.
RESULTS

Mortalitv
A total of 8 rats died during the course of this study. They were distributed among all groups. None of the deaths were considered to be associated with the activity of FCE 22891 1 but, rather, related to a gavage mistake or anesthesia. In the monkeys. 1 male and 4 females receiving 600 mg'kg died as a result of treatment and another female was sacrificed in moribund condition. These deaths all occurred within the first 5 wk of treatment.
Clinical Observations
In rats, the only treatment-related effect was the presence of soft feces, which were seen in almost all high-dose animals of both sexes starting in week 2 and continuing until the end of dosing. Monkeys of both sexes in the high-dose group also exhibited soft feces or diarrhea starting at the end of the first week. After this, a period of vomiting developed and lasted for another week. Marked reduction in food intake, general weakness, sedation, or even lethargy and ataxia were evident in I male and 1 female. These signs progressed in the 5 females and the I male that died. In the remaining male monkeys, soft feces, diarrhea, and reduced food intake persisted even during the recovery period.
In monkeys receiving 400 mg/kg. there was a moderate reduction in food intake, soft feces, and occasional episodes of diarrhea during the first days of the study. These were seen more in females than in males. Infrequent vomiting occurred in 1 male and I female.
In the 100and 200-mg/kg dose groups. monkeys s of both sexes showed only a slight reduction in food In neither species were there any treatment-related ophthalmoscopic findings.
Body Weight
At 26 wk, male rats of all treated groups showed a reduction in body weight that was not dose-related. At the high dose of 1,250 mg, this reduction was evident by week 12 (Table II) .
In monkeys, there was a dose-related loss of body weight in female animals receiving 400 and 600 mg/ kg during the first 4 wk of treatment, which was dramatic at 600 mg/kg (Table II) . After this, the animals receiving 400 mg/kg recovered while treatment continued. Male animals in these groups did show an initial reduction in body weight gain but were later comparable to controls. These effects on body weight were not present during the recovery periods.
Hematology
Mild hematological changes with negligible toxicological implications were seen in rats (Table III) . There were slight decreases in platelet counts only in males of the 1,250-mg/kg dose group at weeks 13 and 26. The values returned to normal over the recovery period. In these same animals, there was a slight reversible decrease in WBC at the end of treatment. In the monkeys, the minimal hematological changes observed were not considered to be relevant in terms of a toxicological effect. Clinical Chemistry (Table IV) A slight increase in azotemia was seen early in the dosing period in both species. Rats showed increased urea values at 500 and 1,250 mg/kg. In the monkeys, only the high dose was involved with increased urea and creatinine levels. All these changes tended to return to control levels before the end of dosing.
Decreases in serum lipids occurred in rats of both sexes in the 500-and 1,250-mg/kg groups, with the effect on cholesterol being more pronounced in females. All these effects were diminished over the recovery period. In the male monkeys receiving 600 mg/kg, there was an increase of about 92% in triglycerides by week 11, which returned to normal by the end of treatment.
In the high-dose rats, a slight decrease in glucose was seen at the end of the treatment in both sexes. This change was preceded by a dose-related increase, which involved males in all treated groups, and then returned to the control values over the recovery period. Equally, in the male monkeys at the high-dose level, there was a slight decrease in glucose by week 11. but at the end of treatment it was similar to that of controls. Fluctuation in glucose levels were within the range of normal biological variation for both species and within the range of normal historical controls for the test laboratory.
Urinalysis (Table V) At the high-dose level, rats of both sexes showed significant decreases in urine volume with a concomitant increase in specific gravity at week 5.
Thereafter, and for the duration of the study, these changes were evident mainly in males. The decrease in volume associated with an increase in specific gravity was also present in the males receiving 500 mg/kg. Over the recovery period, the values returned to those of controls. In monkeys, similar changes occurred at 600 mg/kg mainly in males but were reversible. Rats showed a transient decrease in urinary sodium and an increase in potassium in both sexes but particularly so in males at the 2 highest doses. In monkeys, a fall in sodium was recorded early in the treatment period (week 1 ) at 400 and 600 mg/ kg. This then tended to return to control levels. The low value observed in the high-dose males at the end of the recovery period was considered to be counterbalanced by an increased urinary volume and was of no biological significance.
Urine pH was lowered in rats, particularly in males given 1,250 mg/kg. In monkeys, acidification of the urine was seen at week 11 and continued until the end of treatment but showed a gradual trend toward control values and had returned to normal at the end of the recovery period.
In addition, minor transient changes were seen in the values for protein, ketones, and, only in the monkey, epithelial cells and hyaline casts, particularly at the high-dose level.
Necropsy Findings
In rats, dose-related effects of treatment included emaciation at the high-dose level only: marked dilatation of the cecum, which occurred in both sexes and at all doses, and enlargement of the kidneys with occasional instances of pitting of the surface, which was seen mainly in males. All these were absent by the end of the recovery period. Kidney weight also showed a dose-related increase in both absolute and relative values in male rats of all treatment groups and in females from the 500and 1.250mg/kg dose groups. At the end of the recovery period, the weights were substantially reduced and similar to those of controls. In monkeys, there was an unthrifty appearance and reduced physical condition. which was seen mainly in females of the high-dose group. The kid-neys were the only organs to be grossly affected. They were enlarged in animals of both sexes receiving 400 and 600 mg kg and in females receiving 200 mg. kg. The weights of the kidneys were increased at the same dose levels and, after the recovery period. were still increased when compared to controls.
:l~icroscopic Pathology
In rats of both sexes that had received 500 and 1,250 mg/kg of the test material, the most significant microscopic findings were seen in the renal cortex and involved the tubules and their interstitium.
There was vacuolation and atrophy of tubular epithelial cells with dilation and distension of tubules associated with interstitial fibrosis (Fig. 2 ). Basophilia of tubular epithelial cells was also present and was considered to represent a regenerative change. Histomorphologic changes in treated rats displayed regenerative features by the end of the recovery period (Table VI ). In 4/20 (20%) of the male and 9/21 (42.9%) of the female rats receiving 1,250 mg/kg sacrificed at termination of dosing, there was a simple uniform urothelial hyperplasia of the urinary bladder that was considered to be minimal in severity (Fig. 3) . The same lesion was also present in 7/20 (35%) males and 16/20 (80%) females receiving 500 mg/ kg. In both groups, there was a trend toward recovery in the 6-wk period without treatment. No histological changes were found to correlate with the cecal distension noted in treated animals on gross examination. Decedents showed no treatment-related changes, with the exception of I male rat from the 1,250-mg/kg group, which showed histological changes in the kidneys similar to those noted in rats sacrificed terminally.
In monkeys, despite the gross and functional changes in the kidneys, no morphological findings were evident at the end of treatment in any dose group. The high-dose animals that died before week 6 had significant renal changes consisting of extensive congestion, tubular dilation, and swelling of the tubular epithelial cells, which were present in those animals that died within only a few days of the commencement of treatment. In those that died later in the 5-wk period, a moderate to severe nephropathy was established (Fig. 4 ). In the same animals, there was lymphoid depletion in the lymph nodes and spleen.
DISCUSSION
Results of pharmacokinetic studies in the rat with FCE 22891 shov. that the compound is excreted in the urine at 49% and in the feces at 42% within 3 days following oral administration. The area under the curve (AUC) in male rats was only slightly less than that in females, as was the urinary excretion of radioactivity for comparable doses (2, 6, 7) . In general, there was a tendency toward a slight reduction in urinary excretion, with increasing doses indicating that this function had been saturated (12) . Tissue concentrations after single or multiple doses for up to 21 days further indicate that the kidneys experience the highest concentration with a tendency toward accumulation, followed by the Harderian gland and brown adipose tissue. In monkeys, the AUC was greater than in rats for corresponding dose levels, with that in females being greater than in males. At the high dose, there was again a reduction in urinary excretion, especially in females. Thus, the AUC increases in a less than proportional fashion, further exacerbating the saturation of excretion mechanisms (19) .
From the data available in a 2-wk ancillary toxicokinetic study in monkeys, it has been demonstrated that the animals treated in the safety evaluation studies reported here were adequately exposed to the test compound. AUC values of the active moiety FCE 22101 and its major metabolite obtained after a single dose of 100 mgi'kg were 93 and 20.1 lAg-hr/ml. This dose proved to be without adverse effect. After 14 days of the same dose regime. there were still no noteworthy changes in the phar-macokinetic parameters examined when compared to those following the single dose.
On the basis of AUC values obtained in healthy volunteers employing a therapeutic dose of 1 g/human, which were 8.28 Ilg' hr/ml for the active moiety FCE 22101 and 4.95 jig-hr/ml for the metabolite, it is evident that adequate safety margins have been achieved in the safety evaluation study in monkeys. FCE 22891 caused a reduction in body weight gain at the high-dose levels in male rats and male and female monkeys. At 26 wk, monkeys receiving 400 mg/kg were also slightly affected. During the recovery period, the rate of body weight gain in rats returned to that of controls, but in the male monkeys in the 400and 600-mg/kg dose groups there was no evidence of recovery. There were no female monkeys that survived in the 600-mg/kg group. In rats, the prolonged reduction in body weight gain and the changes in serum lipids revealed a probable but mild interference of the compound with energy metabolism. The functional ability of the rat kidney to concentrate urine exceeds that which occurs in the monkey and in humans with the result that the rat uses less water in urine formation than is the case in the other 2 species (1) . The ranges for specific gravity are 1.040-1.070 in rats, 1.010-1.025 in monkeys, and 1.001-1.035 in humans (1, 10, 14) . Under standard laboratory conditions of NIH-07 diet for the rat. urinary pH ranges from 6.6 to 8.5; in monkeys, comparable values are 7.5-9 and in humans 4.6-8, averaging 6 . In all species, it tends to be lower in males (1, 10, 14) . One target organ in both rats and monkeys in these studies proved to be the kidney, and the changes seen in it were similar for both species. They consisted mainly of cortical tubular degeneration, with evidence of regeneration in those animals that survived the critical early stage of treatment. The changes also regressed over the recovery period. This is consistent with the reports in the literature (15, 21) . Male rats were more affected than females, while female monkeys more than males. Besides the morphological changes, there was also an acidification of the urine, decreases in urinary volume and sodium excretion, and increases in specific gravity. Serum biochemistry revealed, early in the dosing period, increases in urea and, in monkeys, only an increase in creatinine. In rats, the threshold for both morphological and functional changes in the kidney was 500 mg/kg/day. In monkeys, it was 600 mg/kg/day. It is considered probable that the difference in sensitivity between males and females of both species is due to differences in the handling of the relative increase of protein catabolism and renal clearance arising from the sustained stress. The reaction is more intense in male rats and female monkeys. It is strongest in female monkeys where the sustained stress is manifested by lymphoid depletion. Male rats have a higher proximal tubular cell protein metabolizing capacity. Thus, the effects of compound overwhelmed the factors that protect the tubular epithelial cells but did not cause permanent damage. Because female monkeys possess a lower xenobiotic metabolizing capacity than males, the females were more severely affected by this compound, and they sustained permanent damage.
When comparing the effects in the urinary bladder, consideration should be given to the species monkeys and male rats were most severely affected is explained by the fact that female monkeys have a lower xenobiotic metabolizing capacity and the male rats were overburdened by the catabolization in the proximal tubules of the lX2u-globulin.
